ATG9B and central nervous system cancer: Relative to gliomas in the ASCL2‐ATG9B axisLow group, gliomas with high expression of the ASCL2‐ATG9B axis exhibited more GBM and Chr.7.gain/Chr.10.loss, higher age and grade, fewer IDH mutations and 1p/19q codeletion (Figure 5E).